AstraZeneca H1 Results: $30.7B Revenue, Core EPS Up 12%
See more from StockTitan in Google Search…
AstraZeneca posts H1 2026 revenue of $30.7B | AZN SEC Filing
Sustainability Sustainability highlights AstraZeneca received several prestigious recognitions for its sustainability leadership in the quarter. TIME Magazine named…
AstraZeneca Pays $600M for Oral Pill That Beat Chemo in Rare Lung Cancer
For years, patients with a specific genomic subtype of lung cancer faced a stark choice: intravenous chemotherapy, or…
AstraZeneca licenses lung cancer drug Zegfrovy | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca to license lung cancer drug from China’s Dizal Pharmaceutical
Shanghai: Shares in China’s Dizal Pharmaceutical rose 20% on Tuesday, after the AstraZeneca spin-off announced that the drugmaker…
AstraZeneca to license lung cancer drug from China’s Dizal Pharmaceutical
Shanghai: Shares in China’s Dizal Pharmaceutical rose 20% on Tuesday, after the AstraZeneca spin-off announced that the drugmaker…